Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

FDA halts tests of Sanofi drug, acquired in $3.7B buyout, due to side effects
FDA halts tests of Sanofi drug, acquired in $3.7B buyout, due to side effects
The Food and Drug Administration has required Sanofi to stop treating some patients in Phase 3 trials of an experimental multiple sclerosis drug and pause enrollment in the studies in an effort to ...
FDA Accepts Aflibercept sBLA for Treatment of Diabetic Retinopathy
FDA Accepts Aflibercept sBLA for Treatment of Diabetic Retinopathy
If approved, the 16-week dosing regimen could offer certain individuals a potentially longer treatment interval and physicians with greater flexibility to individualize treatment. ...
AstraZeneca Bolsters Blood Cancer Pipeline with $1.27B TeneoTwo Takeover
AstraZeneca Bolsters Blood Cancer Pipeline with $1.27B TeneoTwo Takeover
AstraZeneca is strengthening its oncology pipeline with the acquisition of TeneoTwo, which has an ongoing Phase I trial in relapsed and refractory B-cell non-Hodgkin lymphoma, in a deal valued at u...
FDA Recommends Modified COVID-19 Vaccine Boosters Adapted to Omicron BA.4 and BA.5 Subvariants
FDA Recommends Modified COVID-19 Vaccine Boosters Adapted to Omicron BA.4 and BA.5 Subvariants
The FDA recommended that COVID-19 vaccine manufacturers update their COVID-19 Vaccines with an Omicron BA.4/5 spike protein component to create a bivalent booster vaccine. ...
Sirana Pharma and Pfizer to work on treatment for brittle bone disease
Sirana Pharma and Pfizer to work on treatment for brittle bone disease
German biotech company Sirana Pharma GmbH has entered into a collaborative research agreement with Pfizer Inc. to investigate the potential identification and validation of a novel treatment concep...
After coeliac fail, 9 Meters plots phase 3 in short bowel syndrome
After coeliac fail, 9 Meters plots phase 3 in short bowel syndrome
Two weeks after reporting disappointing results for its lead coeliac disease therapy, 9 Meters Biopharma will draw some comfort from a mid-stage trial of its candidate for short bowel syndrome (SBS...
Dramatic' surprise discovery finds cancer drug delays muscular dystrophy progression in mice
Dramatic' surprise discovery finds cancer drug delays muscular dystrophy progression in mice
A new surprise discovery could hold big implications for muscular dystrophy patients, with researchers finding that an existing cancer drug may delay progression of the hard-to-treat disease. ...
Fast and facile synthesis of antibacterial amino acid Schiff base copper complexes
Fast and facile synthesis of antibacterial amino acid Schiff base copper complexes
Ever since their development in the late 19th century, Schiff bases have been a popular group of organic compounds, owing to their wide variety of desirable properties.  ...
Protecting the brain from dementia-inducing abnormal protein aggregates
Protecting the brain from dementia-inducing abnormal protein aggregates

In order to maintain cellular homeostasis (i.e., a state of equilibrium), cells undergo selective autophagy or self-degradation of unwanted proteins. 

FDA Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for subgroup of Patients with Critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir
FDA Declines Emergency Use Authorization for ZYESAMI® (aviptadil) for subgroup of Patients with Critical COVID-19 at immediate risk of death from respiratory failure despite treatment with approved therapy, including remdesivir
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has declined to issue an Emergency Use Authoriz...
U.S. Government Inks $3.2 Billion Contract With Pfizer-BioNTech for Vaccine Booster Campaign
U.S. Government Inks $3.2 Billion Contract With Pfizer-BioNTech for Vaccine Booster Campaign

The U.S. government has signed a $3.2 billion COVID-19 vaccine supply agreement with Pfizer and BioNTech for 105 million doses.

FDA Pushes Back Review Period for Provention Bio's Diabetes Drug
FDA Pushes Back Review Period for Provention Bio's Diabetes Drug

Provention Bio will have to wait a little bit longer to see if the U.S. Food and Drug Administration will approve its diabetes prevention drug, teplizumab.

Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand